← Leaderboards
Susan J. Knox
Stanford University
$273,368
Attributed
$273,368
Total exposure
10
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $48.1K · FY2006–09$50K$37.5K$25K$12.5K$0
'06
'07
'08
'09
Funding mix
By agency
NIH$273,368 · 10
By mechanism
M01$142,341 · 9
P30$131,027 · 1
Top collaborators
No co-investigators on record.
Most similar at Stanford University
Same institution · by research overlap
- Sandra J. Horning$4,271,994
- Michelle Louise James$4,919,512
- Frederick T Chin$4,587,637
- Robert S Negrin$29,816,136
- Ronald Levy$27,846,042
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectNeoplasm /Cancer Radionuclide TherapyClinical ResearchNeoplasm /Cancer ImmunotherapyResearch PersonnelFundingSafetyResourcesHuman Therapy EvaluationStandards Of Weights And MeasuresClinical TrialsB Cell LymphomaIodineCancer PatientAuthorityEnsureAntitumor AntibodyAgreementDoseFacultyDisease ManagementClinical Trials, Phase IiBiodistributionDoctor Of Medicine
Grant awards (14)
Protocol Review and Monitoring System (PRMS)$48,108
P30 · FY2009 · CA · contact PI
Protocol Review and Monitoring System (PRMS)$45,499
P30 · FY2008 · CA · contact PI
CLINICAL TRIAL: PHASE II STUDY OF BEXXAR IN RELAPSED/REFRACTORY DLCL$683
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: BEXXAR COMBINED WITH EXTERNAL BEAM RADIATION THERAPY FOR PATIENT$455
M01 · FY2008 · RR · contact PI
Protocol Review and Monitoring System (PRMS)$37,420
P30 · FY2007 · CA · contact PI
PHASE II STUDY OF BEXXAR IN RELAPSED/REFRACTORY DLCL$2,340
M01 · FY2007 · RR · contact PI
PHASE II STUDY OF BEXXAR IN RELAPSED/REFRACTORY DLCL$1,779
M01 · FY2006 · RR · contact PI
ANTI B1 ANTIBODY FOR NONHODGKINS LYMPHOMA$134,676
M01 · FY2001 · RR
ANTI B1 ANTIBODY FOR NONHODGKINS LYMPHOMA$0
M01 · FY2001 · RR
ANTI-B1 (MURINE) IN CHEMOTHERAPY-REFRACTORY LOW GRADE NONHODGKIN'S LYMPHOMA$602
M01 · FY2000 · RR
STUDY OF 90 YTTRIUM/DOTA/BIOTIN LOCALIZATION IN ADVANCED CANCER$602
M01 · FY2000 · RR
PHASE II MULTICENTER TRIAL OF 90 YTTRIUM DOTA BIOTIN IN SUBJECTS W/ CANCER$602
M01 · FY2000 · RR
IODINE ANTI B1 MURINE RADIOIMMUNOTHERAPY FOR CHEMOTHERAPY LYMPHOMA$602
M01 · FY2000 · RR
ANTI B1 ANTIBODY FOR NONHODGKINS LYMPHOMA$0
M01 · FY2000 · RR